Ligand Pharmaceuticals Inc (NASDAQ:LGND)
| 75.29 Delayed Data As of Jun 02 |  +4.09 / +5.74%Today’s Change | 45.25 Today|||52-Week Range 85.70 | +12.71% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Revenue and Income | Net Revenues | 71.9M | 109.0M | 141.1M | 251.5M | |
| Cost of Goods Sold | 3.2M | 4.9M | 5.0M | 5.4M | ||
| Depreciation And Amortization | 2.6M | 11.3M | 12.5M | 16.7M | ||
| Operating Expenses | Gross Income | 66.1M | 92.8M | 123.6M | 229.3M | |
| General Expenses | 37.8M | 47.8M | 55.5M | 65.6M | ||
| Research And Development | 13.4M | 21.2M | 26.9M | 27.9M | ||
| Total Operating Expenses | 43.6M | 64.1M | 73.0M | 87.7M | ||
| Non-Operating Expenses | Operating Income | 28.3M | 44.9M | 68.1M | 163.7M | |
| Extraordinary Credit | 27.2M | 300.0K | 3.2M | 5.4M | ||
| Extraordinary Charge | -5.8M | -4.4M | -2.6M | 0.00 | ||
| Pre-Tax Equity Earnings | -5.1M | -23.1M | -2.0M | 50.2M | ||
| Interest Expense On Debt | 11.8M | 12.2M | 11.4M | 48.3M | ||
| Other Expenses | 2.5M | 2.4M | 2.0M | -11.7M | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | 35.3M | 8.0M | 57.2M | 173.3M | |
| Income Taxes | -192.1M | -10.3M | -44.7M | -30.0M | ||
| Minority Interest | -2.4M | 0.00 | 0.00 | 0.00 | ||
| Extraordinary Items | 0.00 | 731.0K | 0.00 | 0.00 | ||
| Net Income | 229.8M | -2.4M | 12.6M | 143.3M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 19.8M | 20.8M | 21.0M | 21.2M | |
| Shares To Calculate EPS Diluted | 21.2M | 20.8M | 23.5M | 24.1M | ||
| Earnings Per Share | EPS | $10.83 | -$0.08 | $0.53 | $5.96 | |
| EPS Diluted | $10.83 | -$0.11 | $0.53 | $5.96 | ||
